Business Wire

Philip Morris International Launches New IQOS ILUMA in Japan to Accelerate the Achievement of a Smoke-Free Future

17.8.2021 09:30:00 EEST | Business Wire | Press release

Share

Philip Morris International Inc. (PMI) (NYSE: PM) today announced the launch of IQOS ILUMA, the latest and most innovative addition to their growing portfolio of smoke-free products for adults who would otherwise continue to smoke or use nicotine products. Today, this range of better and satisfying alternatives to cigarettes includes multiple generations of the IQOS tobacco-heating system, the No. 1 heated tobacco product in the world.1 Uniquely, the new IQOS ILUMA becomes the brand’s first tobacco-heating system to introduce induction-heating technology, which utilizes no blade and requires no cleaning.

“Our objective is a world without cigarettes; a world where cigarettes are replaced by smoke-free alternatives that are a better choice than continued smoking,” said PMI CEO Jacek Olczak. “We have launched several generations of our IQOS heated tobacco system; expanding our portfolio to offer constantly improved, science-backed solutions that take advantage of advancements in technology and address pain points heard from consumers. This commitment to continuous innovation plays a significant role in our ambition to deliver a smoke-free future. The launch of IQOS ILUMA, our most innovative device yet, gives adult smokers another better choice and represents an important leap forward in our efforts to accelerate the end of smoking.”

The IQOS ILUMA series offers two devices in Japan: IQOS ILUMA PRIME and IQOS ILUMA. Both devices use new induction-heating technology but offer different designs to allow adult users to select the device that best suits their needs and preferences.

The innovative heating technology in these devices is the SMARTCORE INDUCTION SYSTEMTM that heats the tobacco from within the new TEREA SMARTCORE STICKTM. These newly designed sticks are to be used only with IQOS ILUMA,2 which features an auto-start function that detects when the TEREATM stick is inserted and automatically turns on the device. These bladeless devices offer a cleaner way to heat tobacco from the core, without burning it, to provide a more consistent experience, no tobacco residue, and no need to clean the device. Additionally, they generate no combustion and no smoke, and PMI’s market research indicates that IQOS ILUMA provides a more pleasurable experience compared to previous IQOS generations.3

“IQOS ILUMA is our most innovative offering to-date and the new flagship in our portfolio of science-backed, smoke-free products. Its breakthrough induction-heating technology heats tobacco from within, without burning, so there’s no smoke, no ash and, like previous IQOS devices, it emits, on average, 95% lower levels of harmful chemicals compared with cigarettes,”4,5 said Michele Cattoni, Vice President Heated Tobacco Platforms at PMI. “However, unlike our previous tobacco-heating systems, IQOS ILUMA has no blade. That means no tobacco residue or cleaning—ever. With this, and other product features, we aim to address consumer pain points that may have hindered some adult smokers from beginning or maintaining their journey away from cigarettes in the past.”

IQOS ILUMA PRIME and IQOS ILUMA are available in Japan for pre-order on IQOS.com beginning August 17, 2021 and for purchase at IQOS stores on August 18, 2021.

As of June 30, 2021, PMI’s smoke-free products are available in 67 markets.6 The company has stated its ambition to be present in 100 markets with its smoke-free products by 2025. There are more than 20 million users of the IQOS tobacco heating system globally, and PMI estimates that more than 73% (approximately 14.7 million) of these men and women have switched completely to IQOS and stopped smoking with the balance in various stages of switching.7 PMI’s ambition is that by 2025 at least 40 million PMI cigarette smokers who would otherwise continue to smoke will have switched to smoke-free products. Furthermore, the company’s ambition is that more than half of its net revenues will come from smoke-free products by 2025.

IQOS ILUMA AND IQOS ILUMA PRIME

IQOS ILUMA PRIME is available in a new design that uses elegant, anodized aluminum combined with a texture wrap. The device is available in four colors and is customizable both in terms of connected features via the user’s smartphone and offline with a wide range of accessories, including charger wraps and holder rings. The design of IQOS ILUMA is similar to that of previous IQOS generations but provides an enhanced tobacco experience with improved draw and stick-by-stick taste consistency—available in five colors with further accessory options, such as holder rings and interchangeable doors. Both devices offer adult users the ability to have two consecutive uses without recharging the holder and include advanced features that can be enabled or disabled—by the IQOS app—such as smart gestures, auto-start, various illumination modes, alerts, and the ability for the user to lock and unlock their device when needed. IQOS ILUMA is our most robust device to date, and, as it has no blade, there’s no need to clean the device.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2021, PMI’s smoke-free products are available for sale in 67 markets in key cities or nationwide, and PMI estimates that approximately 14.7 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com.

1 Source: PMI global estimate of total in-market sales of heated tobacco units as of December 2019 (excluding China and U.S.).
2 IQOS ILUMA is designed to be used only with TEREA SMARTCORE STICKS. IQOS ILUMA and TEREA SMARTCORE STICKSTM must not be used with previous IQOS generations, as this may cause damage to the device. As TEREA SMARTCORE STICKSTM contain a sharp metal part that can cause serious injury if swallowed, they must be kept out of reach of children and pets, and must not be ingested or disassembled.
3 Source: Studies conducted in Italy and Japan with a total of 714 IQOS users, November 2020 to March 2021.
4 Important information: It does not necessarily equal a 95% reduction in risk. IQOS is not risk-free and provides nicotine, which is addictive. Only for use by adults.
5 ”95% less” represents the average reductions in levels of a range of harmful chemicals (excluding nicotine) compared to the smoke of a reference cigarette (3R4F). See Important Information on www. iqos.com.
6 Source: Philip Morris International 2021 Second-Quarter Results.
7 Source: Philip Morris International 2021 Second-Quarter Results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information and assets, please contact:

Philip Morris International

Bryson W. Thornton
+41 (0) 58 242 4500
Bryson.Thornton@pmi.com

Blaine Dodds
+41 (0) 58 242 4500
Blaine.Dodds@pmi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NetApp Completes Acquisition of PEAK:AIO to Accelerate Zettabyte-scale AI Deployments2.11.2026 15:00:00 EET | Press release

NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it completed the acquisition of PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. With this acquisition, NetApp can leverage metadata services and parallel namespace innovations to power the fastest storage on the planet, NetApp Novus, to support zettabyte-scale file systems for the most demanding workloads of AI clouds and GPU-as-a-service providers. For the best AI infrastructure economics, organizations need to keep GPU resources continuously supplied with data without bottlenecks. The acquisition advances NetApp’s strategy for the next phase of AI infrastructure by bringing PEAK:AIO’s metadata and parallel file system expertise together with NetApp ONTAP, giving customers a path to AI-scale storage that combines high concurrency and massive namespace growth with the resilience, security, and operational simplicity enterprises already trust

HistoSonics Receives Regulatory Approval in Singapore, Advancing Expansion Across Asia-Pacific2.11.2026 15:00:00 EET | Press release

HistoSonics today announced that the company has received market authorization from Singapore’s Health Sciences Authority (HSA) for its Edison® Histotripsy System (under the device name HistoSonics Histotripsy System), marking another significant milestone in the company’s continued international expansion and creating new opportunities to advance access to histotripsy throughout the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102090757/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image-guided platform that uses the mechanical properties of focused ultrasound, known as histotripsy, to mechanically destroy and liquefy unwanted tissue and tumors. The technology offers a fundamentally new approach to tissue destruction without the need for invasive procedures, radiation, or thermal energy. The Edison System is currently authorized for the destruction of liver

Bentley Systems Announces Seequent’s Acquisition of Seismic Interpretation Software Company Eliis2.11.2026 15:00:00 EET | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that Seequent, The Bentley Subsurface Company, has acquired seismic interpretation software company Eliis. The acquisition will enrich Seequent’s capabilities in geophysics with seismic data interpretation and further advance subsurface understanding to help solve complex global challenges. Eliis’ global team of more than 100 geoscientists, technical specialists, and researchers will join Seequent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029964674/en/ 3D view from PaleoScan showcasing recent advancements in seismic interpretation workflows that support prospect evaluation and exploration decision-making Founded in 2007 and with headquarters in Montpellier, France, Eliis develops advanced seismic interpretation software that helps geoscientists process and analyze seismic imaging data to build detailed model

NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI2.11.2026 13:45:00 EET | Press release

NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include: Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint. Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance review completion reached 99% and the employee survey response rate reached 89%. NIQ also introduced three new leadership development tracks, while Employee Assistance Program

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer2.11.2026 13:42:00 EET | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable, locally advanced colon cancer. The manuscript, titled “Preoperative botensilimab with or without balstilimab for patients with resectable, locally advanced pMMR or dMMR colon cancer: the UNICORN trial by GONO,” was published in Nature Medicine and is available at DOI 10.1038/s41591-026-04710-1. The UNICORN trial enrolled 56 patients in four non-randomized cohorts of 14, evaluating BOT alone or BOT+BAL in mismatch repair proficient/microsatellite stable (pMMR/MSS) and mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colon cancer. The study ass

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye